Advanced Filters
noise

Human Papilloma Virus Clinical Trials

A listing of Human Papilloma Virus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 203 clinical trials
L Lisa Barroilhet, MD

Testing RG1-VLP Vaccine to Prevent HPV-related Cancers

This phase I trial tests the safety, side effects, and best dose of RG1-virus-like particle (VLP) in preventing human papillomavirus (HPV)-related cancers in women. RG1-VLP is a vaccine that aims to protect against rare HPV types not targeted by currently approved HPV vaccines. HPV is a common sexually-transmitted infection that …

18 - 60 years of age Female Phase 1
C Clinical Trial Referral Office

Prospective Assessment of HPV Associated Anogenital Pathology in Female Patients and Female Partners of Patients With Confirmed HPV Associated Oropharyngeal Carcinoma, PAP-OP Study

This study evaluates how often women with throat (oropharyngeal) cancer or who have a partner with oropharyngeal cancer get anogenital infections with high risk, potentially cancer-causing types of human papilloma virus (HPV).

18 years of age Female Phase N/A
K Katja Gümüs, Dr. med

PANHPVAX, Study of a New HPV Vaccine in Healthy Volunteers

First-in-human, phase I, single-center, open-label, dose-escalation trial in healthy volunteers. Investigation of safety and tolerability of ascending doses of PANHPVAX, a vaccine against human papilloma L2 antigens formulated with cdA (adjuvant) as compared to the formulation without cdA.

18 - 45 years of age All Phase 0
B Barbara Burtness, MD

5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

This study is being done because both 5-azacytidine and nivolumab can influence the immune system's response to HPV-associated head and neck cancer, and we wish to evaluate whether taking 5-azacytidine will make HPV-associated head and neck cancer more sensitive to treatment with nivolumab. 5-Azacytidine (5-AZA) is a chemotherapy, and nivolumab …

18 years of age All Phase 2
W Warner K Huh, MD

HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia

The primary goal of this phase I open label study is to determine the safety and tolerability of pNGVL4aCRTE6E7L2 DNA vaccine, as administered by intramuscular (IM) injection with TriGrid™ electroporation to both HIV- or HIV+ adult female subjects (≥ 19 years), with biopsy confirmed cervical intraepithelial (CIN) II or III …

19 years of age Female Phase 1
S Sarah Dutkevitch, RN

ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the Oropharynx

This study is a prospective phase II trial, designed to assess the efficacy and feasibility of adjuvant treatment deintensification guided by ctHPVDNA levels for patients with HPV+OPSCC who undergo transoral surgery and neck dissection.

18 years of age All Phase N/A
G Giorgio Bogani

Multimodality Treatments of HPV-related Lesions of the Female Genital Tract

Cervical cancer is one of the most preventable types of cancer, as it develops over an extended period, and its causative agent is well-known. Persistent infection with human papillomavirus (HPV) is the primary factor causing cervical cancer. Generally, persistent HPV infection leads to cervical dysplasia (also known as cervical intraepithelial …

18 years of age Female Phase N/A
C Clinical Trials and Translational Medicine Divsion

Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly

Previous studies of this type of head and necl cancer have shown high rates of cancer control but result in many short and long term side effects when treated with high dose radiation and chemotherapy. Recently, investigators have noticed similar high rates of cancer control in small numbers of patients …

65 - 99 years of age All Phase N/A
P Peter H Ahn, MD

De-escalation of Adjuvant Radiation for Low-Risk HPV Oropharyngeal Cancers

The goal of this clinical trial is to learn whether for intermediate-risk patients who have undergone Transoral Robotic Surgery for HPV/p16(+) oropharyngeal cancer and have minimal smoking history, whether these patients can be treated with a lower-than standard dose, with omission of the primary site in the oropharynx. The main …

18 years of age All Phase N/A
Y Ying Zheng, Dr.

HPV Genotype Attribution and Disease Burden of Anal Cancer in China

To demonstrate HPV prevalence and its genotype distributions in anal cancer in China and to describe demographic and clinical features of HPV-related anal cancer in China; To describe the epidemiological characteristics ,trends and of disease burden of anal cancer in China

years of age All Phase N/A

Simplify language using AI